Publication | Open Access
Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease
57
Citations
1
References
2021
Year
3C-like ProteaseBardoxolone MethylMedicineImmunologyClinical TrialsTherapeutic EfficacyAntiviral Drug DevelopmentAntiviral TherapyAntiviral DrugPharmacology
Dear Editor
| Year | Citations | |
|---|---|---|
Page 1
Page 1